Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
mechanism:
Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) ·
'"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1)
uses:
Preventive treatment of migraine in adults (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"' (1) ·
'"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1)
starting dose:
1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) ·
100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) ·
150 mg PO once daily; titrate to 300 mg if needed (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
fda max:
routes:
onset:
duration:
halflife: (Click arrow to add another value)
bioavailability:
pregnancy:
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.